ARS Pharmaceuticals awarded Chief Commercial Officer Margaret Ekins 1,001,738 derivative securities on September 1, 2026. Her ownership after the transaction was 1,001,738 derivative securities, giving investors a precise view of the reported executive holding and the transaction’s resulting position.
Key Highlights
- Margaret Ekins serves as Chief Commercial Officer of ARS Pharmaceuticals.
- The transaction took place on September 1, 2026.
- The reported transaction used SEC code A.
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) awarded Chief Commercial Officer Margaret Ekins 1,001,738 derivative securities. The transaction leaves Ekins with ownership of 1,001,738 derivative securities, matching the amount awarded.
Executive Award Leaves 1,001,738 Securities Owned
Ekins’ transaction was recorded on September 1, 2026, under SEC transaction code A. The award involved derivative securities of ARS Pharmaceuticals. Ekins is identified as the company’s Chief Commercial Officer. Her reported ownership following the transaction stands at 1,001,738 derivative securities. Both figures are 1,001,738, with the first representing the securities awarded and the second representing Ekins’ holdings after the transaction. ARS Pharmaceuticals is listed on Nasdaq under SPRY.
FAQs
Q: What did Margaret Ekins receive from ARS Pharmaceuticals?
A: ARS Pharmaceuticals awarded Chief Commercial Officer Margaret Ekins 1,001,738 derivative securities. The filing records the award on September 1, 2026, under SEC transaction code A.
Q: How many derivative securities does the ARS Pharmaceuticals executive own?
A: Margaret Ekins owned 1,001,738 derivative securities of ARS Pharmaceuticals after the transaction. She is identified as the company’s Chief Commercial Officer.
Q: What transaction code was used for the SPRY insider transaction?
A: The ARS Pharmaceuticals transaction involving Margaret Ekins was recorded with SEC transaction code A. The reported award covered derivative securities.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.